Significantly superior to Salofalk tablets for the treatment of acute distal ulcerative colitis (proctosigmoiditis) thanks to
• Dual-release technology that delivers the drug to the terminal ileum and colon in a pH-dependent manner, and a matrix core that ensures continuous release of the active substance along the entire colon to the rectum
• Granule formulation with a large total surface area allowing for reliable delivery and consistent distribution of the active substance
Leifeld L et al. Aliment Pharmacol Ther. 2011; 34: 1115 – 1122.
Product Highlight - Salofalk
12 Mar 2021